Affluent Medical Stock: price and insider trades · France
1 insider bought €110k of shares over the last 90 days, the latest by HOLDING INCUBATRICE SERIE I, filed 28 Oct 2026.
Affluent Medical: what insiders have been doing
Every trade that managers of Affluent Medical disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Aix-en-Provence, France. 2 insiders have disclosed 5 filings since 7 November 2025.
Only purchases show up on the open market, 5 purchases in all worth €7.7M, filed by 2 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 chief executives and 1 board member. Biggest ticket of the year: €5.0M, bought by Truffle Capital SAS and made public on 4 February 2026.
With 5 filings in twelve months, the company is quieter than the median of 7 filings across the 314 companies we follow on the same exchange. The full history, which starts in 2022, counts 7 purchases against 1 sale.
The clock since the last published purchase (28 October 2026) now reads 11 days. Filings reach the AMF feed a median of 4 days after the trade. The legal deadline for notifying a trade is three business days (MAR article 19).
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Aix-en-Provence, France
Source: Wikidata (CC0).
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended December 2024 · cache
- 1,868 shares@ €5.350.0027% mcap9.1% of flowActionAcquisition hors marchéISIN FR00133330772026DD1146687Canonical exit: 24 Jan 2027 (T+90)
- 7,470 shares@ €5.350.012% mcap100.0% of flowActionAcquisition hors marchéISIN FR00133330772026DD1145858Canonical exit: 17 Jan 2027 (T+90)
- 11,206 shares@ €5.350.018% mcap100.0% of flowActionAcquisition hors marchéISIN FR00133330772026DD1143232Canonical exit: 3 Jan 2027 (T+90)
- 773,809 shares@ €3.360.66% mcap11.9% of flowActionAcquisition hors marchéISIN FR00133330772026DD1123892Canonical exit: 24 Sept 2026 (T+90)
- 2,136,751 shares@ €2.3422.9% of flowActionAcquisition hors marchéISIN FR00133330772026DD1092720Canonical exit: 3 May 2026 (T+90)
- 16,176 shares@ €1.360.1% of flowActionAcquisition hors marchéISIN FR00133330772025DD1064624Canonical exit: 18 Jan 2026 (T+90)
- 18,382 shares@ €1.360.1% of flowActionAcquisition hors marchéISIN FR00133330772025DD1059546Canonical exit: 19 Oct 2025 (T+90)
- 2,479,411 shares@ €1.3815.6% of flowTitre de créanceEuroclearISIN FR00133330772024DD986552
- 1,419,871 shares@ €1.5610.1% of flowActionEuronext ParisISIN FR00133330772024DD949188
- 14,820 shares@ €1.32100.0% of flowActionEuronext ParisISIN FR00133330772023DD891643
- 14,820 shares@ €0.032.2% of flowBSAR - bons de souscription d'action remboursableEuronext ParisISIN FR001400FL382023DD891643-T2
- 6,363,034 shares@ €1.3238.4% of flowActionEuronext ParisISIN FR00133330772023DD888174
- 6,363,034 shares@ €0.030.9% of flowBSAREuronext ParisISIN FR001400FL382023DD888175
- 1,637,931 shares@ €2.32100.0% of flowActionEuronext ParisISIN FR00133330772022DD862308
- 275,000 shares@ €0.04100.0% of flowDroits Préferentiel de Souscription (DPS)Euronext ParisISIN FR00133330772022DD860723
15 of 15 declarations
About Affluent Medical
Affluent Medical is a French clinical-stage medtech company, historically listed under ticker AFME and ISIN FR0013333077, specializing in the development and industrialization of innovative implantable medical devices. Headquartered in Aix-en-Provence and admitted to trading on Euronext Paris in June 2021, the company was originally backed by Truffle Capital and was founded with the ambition of becoming a global reference in urology and interventional cardiology. Its strategic positioning is built around breakthrough technologies designed to address major unmet medical needs, particularly urinary incontinence and mitral valve disease. In 2026, the company announced a rebranding to Carvolix while keeping the same ISIN, highlighting a broader strategic evolution of its identity and technology platform.
Affluent Medical’s business model is centered on a portfolio of advanced devices still in clinical development. Its lead programs include Kalios™, a percutaneously adjustable mitral annuloplasty ring intended to reduce repeat surgery after valve repair; Epygon, a biomimetic mitral valve replacement; and Artus, a robotic-assisted artificial urinary sphincter. These products are designed to mimic human physiology as closely as possible, combining minimally invasive implantation with the potential to improve patient outcomes and simplify procedures for physicians. The group’s historical portfolio has been protected by a broad patent estate, supporting its technological differentiation and long-term value proposition.
Read moreShow less
The company has reached several important industrial and regulatory milestones. In 2024, it signed strategic agreements with Edwards Lifesciences, including an upfront payment of €15 million, an equity investment, and an exclusive purchase option on Kephalios, the subsidiary developing Kalios. These agreements strengthened Affluent Medical’s industrial and financial credibility while preserving key rights over its transcatheter technologies. Clinically, the company continued advancing studies on Kalios, Epygon and Artus, with a particular focus on the U.S. market for structural cardiology and on Europe for the initial commercialization pathway in certain indications. It also reported progress in the clinical assessment of Artus in women, broadening its potential commercial addressable market.
Affluent Medical is notable for its international development strategy, targeting Europe, the United States and Asia. It remains a high-R&D, pre-commercial medtech company, but one supported by partnerships, regulatory validation and a gradually strengthening capital markets profile. Its recent trajectory, marked by successive financings, growing market visibility and a more focused portfolio, reinforces its ambition to establish itself as a leading specialist in next-generation medical implants.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
